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Abstract
FusE mutants are fusidic acid-resistant small colony variants (SCVs) of Staphylococcus aureus that can be selected with
aminoglycosides. All FusE SCVs have mutations in rplF, encoding ribosomal protein L6. However, individual FusE mutants
including some with the same mutation in rplF display auxotrophy for either hemin or menadione, suggesting that
additional mutations are involved. Here we show that FusE SCVs can be divided into three genetic sub-groups and that
some carry an additional mutation, in one of the genes required for hemin biosynthesis, or in one of the genes required for
menadione biosynthesis. Reversion analysis and genome sequencing support the hypothesis that these combinations of
mutations in the rplF, hem, and/or men genes can account for the SCV and auxotrophic phenotypes of FusE mutants.
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Introduction
The small colony variant (SCV) phenotype of Staphylococcus
aureus, is associated with reduced susceptibility to aminoglycosides
and auxotrophy for hemin, menadione, thiamine or thymidine [1].
S. aureus SCVs are often isolated from patients with persistent
recurring infections such as chronic osteomyelitis and skin and
soft-tissue infections. These pathogenic traits have been attributed
to the ability of SCVs to invade and survive inside nonprofessional
phagocytes, such as epithelial and endothelial cells, where they are
thereby shielded from the immune response. [1]
The phenotypes associated with S. aureus SCV’s are thought to
result from a dysfunctional electron transport system [1,2,3,4,5,6].
These phenotypes include reduced susceptibility to aminoglycoside
antibiotics due to alterations in the proton motive force on which
they depend for drug uptake, and selection with aminoglycosides
can be used to isolate SCV mutants [7]. Because of their very slow
growth rates in the laboratory, SCVs are susceptible to overgrowth
by faster-growing variants arising from within these mutant
populations. The observation of phenotypic instability among
many SCV strains initially led to controversy over whether SCV’s
were phenotypic variants or genetic mutants, however it is now
clear that certain genetic mutations lead to the SCV phenotype.
Thus, selected or constructed mutations in the following genes
have been shown to lead to the SCV phenotype: delta-
aminolevulinic acid dehydratase (hemB) [8,9], ferrochetalase (hemH)
[10], 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylic acid
synthase/2-oxoglutarate decarboxylase (menD) [9], and cyto-
chrome oxidase (ctaA) [11]. In clinical strains the genetic basis of
SCV phenotypes has been reported in only a few cases. In
thymidine-auxotrophic SCVs from cystic fibrosis patients, muta-
tions were identified in the thymidylate synthase gene, tyhA [12,13]
and in menadione-auxotrophic SCVs collected from patients with
chronic osteomyelitis the mutations causing the SCV phenotype
were localized to menB, the gene encoding naphthoate synthase
[14].
Fusidic acid (FA) is an antibiotic used as a single agent or in
combination therapies for the treatment of S. aureus infections. FA
acts by binding to the translation elongation factor EF-G when in
complex with the ribosome during translation. FA binding
prevents the release of EF-G from this complex and interrupts
further protein synthesis. In S. aureus several genetically distinct
classes of FA-resistance mechanisms have been identified. The
FusA class results from mutations within the gene fusA which
encodes EF-G thereby affecting EF-G structure and fusidic acid-
target binding [15,16,17,18]. A subset of FusA mutants display the
SCV phenotype and are auxotrophic for hemin [18]. The FusB,
FusC and FusD classes carry fusidic acid resistance genes which
can be horizontally-transmitted and produce proteins that protect
EF-G from fusidic acid binding [19,20,21,22,23]. The FusE class
of mutants, all of which display the SCV phenotype, harbour
knockout-mutations (mutations causing frameshifts, nonsense
codons, and mutated start codons) in rplF, the gene coding for
ribosomal protein L6 [18]. Note that fusidic acid-resistant mutants
with the SCV phenotype can be selected either with fusidic acid or
with aminoglycosides such as kanamycin [18]. Some FusE mutants
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menadione [18]. The phenotypic variation within the FusE-group
cannot be explained by the rplF mutations alone, since mutants
with identical mutations in rplF can display either hemin or
menadione auxotrophy [18]. This implies that there must be
additional mutations in some, or all, of the FusE mutant strains.
In the present study the mutational status of the FusE fusidic
acid-resistant mutant group is characterized, and we show that this
group encompasses three genetically distinct subgroups, all of
which harbour rplF mutations. Two of these subgroups carry
additional mutations in genes associated with hemin or menadione
biosynthesis, which can explain their hemin or menadione
auxotrophy. We also report on the selection and identification of
mutations that compensate for the slow growth phenotype of FusA
and FusE SCV’s.
Results
Genetic analysis of FusE class mutants
FusE mutants are FA-resistant, and harbour mutations in rplF
[18]. FusE mutants have also been placed in phenotypic subclasses
depending on whether they are auxotrophic for hemin or
menadione. Different FusE mutants demonstrate significantly
different generation times in LB of 50–200 min compared to the
AH001 WT parent strain (24 min) [18]. Note that the growth rate
of all of the SCV’s can be rescued by the addition of hemin or
menadione, as appropriate, to the growth media [18]. These
differences in auxotrophy and growth rate suggested that at least
some FusE mutants carry additional mutations that lead to the
unique phenotypes observed. 23 of the 24 partially characterized
FusE mutants [18] were chosen for this investigation (Table 1).
Only the slowest growing FusE mutant, strain AH330 [18], was
dropped from this investigation due to its extreme phenotypic
instability. Because the SCV phenotype in S. aureus has been linked
to defects in hemin and menadione biosynthesis all known genes
(Table S1) predicted to be involved in these pathways were PCR-
amplified and sequenced for the set of mutants investigated in this
study, according to their observed auxotrophy (Table 1). We also
re-sequenced rplF in each mutant to confirm the presence of the
expected mutation. In 11 of 15 hemin-auxotrophic FusE mutants
(AH380 to AH357, Table 1), the original rplF mutations [18] were
confirmed, and no additional mutations were identified in the gene
set sequenced (Table S1). The rplF mutations in the remaining 4
hemin-auxotrophic FusE mutant strains (AH374 to AH384,
Table 1) were confirmed and in addition, mutations were also
identified in hemA, hemB or hemH. All 4 hem mutations caused single
amino acid substitutions.
The rplF mutations in all 8 menadione-auxotrophic mutants
(AH378 to AH386, Table 1) were confirmed [18] and in addition
mutations were identified in menA, menB or gerC3 in these mutants.
Within this group of strains we now place AH358 which was
previously mistakenly listed as a hemin auxotroph [18]. The
mutations associated with menadione-auxotrophy caused single
amino acid substitutions, with the exception of a frameshift
mutation in gerC3 in strain AH351 and a nonsense codon in menB
in strain AH386, both near the end of the respective gene. The
absence of randomly distributed frameshift or nonsense mutations
in these genes in this strain group raises the possibility that the
mutant proteins may retain some activity. Not finding a mutation
in a suspect gene does not rule out the possibility that mutations at
other sites could be responsible for the phenotype. To test whether
we had identified all mutations relevant to the phenotypes, we
arbitrarily chose two mutant strains (AH357, AH358) for
comparative genome sequencing (CGS, see Materials and
Methods for details) and comparison to parent strain AH001
(Table 1). CGS confirmed the expected genotypes of each mutant
and did not reveal the presence of any additional mutations
(additional SNPs were called by CGS but ruled out as false
positives after local re-sequencing; see Materials and Methods).
While we cannot rule out the possibility that there may be
additional mutations in strains that were not analysed by CGS, for
those strains that were tested the results were in agreement with
that from sequence analysis of the listed suspect genes affecting
hemin and menadione biosynthesis (Table S1).
Thus, our data now demonstrate that the FusE class of mutants
comprise three sub-groups: the FusE L6 class (rplF single mutants),
the FusE L6-Hem class (rplF and hem double mutants) and the
FusE L6-Men class (rplF and men double mutants). Based on these
data we hypothesized that the phenotypes of FusA SCV [18] and
FusE L6 mutants could be explained by single mutations in fusA or
rplF, respectively. Further, that the phenotypes of FusE L6-Hem
and FusE L6-Men mutants could each be explained by the
presence of at least two mutations, one affecting rplF and another
in a gene involved in either hemin or menadione biosynthesis,
Table 1. Genetics of FusE class mutants.
Identified mutations
Strain fusA rplF Men/Hem gene
a
FusE L6
AH380 WT 21 nt 158 (FS
b) none
AH352 WT 21 nt 106 (FS) none
AH377 WT +1 nt 23 (FS) none
AH348 WT TGA stop nt 244 none
AH370 WT TAA stop nt 229 none
AH346 WT 21 nt 238 (FS) none
AH333 WT TAA stop nt 249 none
AH392 WT 21 nt 383 (FS) none
AH379 WT TAA stop nt 418 none
AH349 WT 21 nt 404 (FS) none
AH357
c WT TAA stop nt 301 none
FusE L6 Hem
AH374 WT 25 nts 2362240 (FS) hemA Ala190Glu
AH339 WT 21 nt 144 (FS) hemB Gly87Asp
AH337 WT 21 nt 220 (FS) hemB Gly87Asp
AH384 WT 21 nt 221 (FS) hemH Gly209Asp
FusE L6 Men
AH378 WT 21 nt 221 (FS) menB Arg101Leu
AH351 WT 24 nts 45–48 (FS) gerC3 21F Sn t9 1 9
AH358
b WT 21 nt 423 (FS) menB Val58Phe
AH360 WT ATA Start nt 3 menA Arg19Ser
AH383 WT TAA stop nt 139 menA Gly87Asp
AH362 WT TAA stop nt 282 menA Asp81Tyr
AH390 WT +1F Sn t8 4 menB Arg 53 Cys
AH386 WT 21F Sn t9 0 menB Gln 204 stop
aAll genes known to be involved in hemin and menadione biosynthesis were
sequenced in the respective groups to identify mutations, see Table S1.
bMutation is predicted to cause a ribosomal frameshift (FS) during translation of
the mRNA.
cAH357 and AH358 were also analysed by CGS in comparison with wild-type
8325-4.
doi:10.1371/journal.pone.0028366.t001
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reverse the mutant phenotypes by selection of second-site
compensatory mutations in each of the affected genes. To test
this we performed a reversion analysis by selecting growth-
compensated mutants of strains belonging to each of the FA-
resistant SCV classes (FusA SCV, FusE L6, FusE L6-Hem, and
FusE L6-Men).
Analysis of growth-compensated FusA SCV mutants
FusA SCVs are caused by mutations in elongation factor EF.G.
From the FusA SCV group [18], independent growth compen-
sated mutants were selected from four different strains (AH347,
AH350, AH364 and AH366, Table 2) as described in Materials
and Methods. In all mutants the fusA gene was sequenced to
identify possible compensatory mutations that may have occurred
in these fast-growing derivatives. In most cases intragenic second-
site mutations were identified in fusA (Table 2), the only exception
being strain AH537 where the compensatory mutation was a
reversion back to the WT fusA sequence. Changes in KAN and FA
MICs were also measured. Most compensatory mutants had
decreased KAN and FA MIC’s compared to the parent strain,
although it remained higher than the original WT strain NCTC
8325-4 MIC (Table 2). This is in agreement with published data
on the MICs associated with intragenic mutations in fusA [15] and
suggests that the double mutants do not fully restore a wild-type
EF-G phenotype. The only strain in which MIC was identical to
that of the wild-type was AH537 in which the fusA mutation had
reverted to the wild-type sequence. In a few of the mutants the
compensatory fusA mutation actually led to a small increase in FA
MIC (AH519, AH521, AH530, AH539 and AH541) or KAN
MIC (AH527, and AH541). This finding is of interest since these
mutants were not selected in the presence of fusidic acid or
kanamycin. Mutant AH540 did not have a fusA compensatory
mutation and displayed increased FA and KAN MICs compared
to parent strain AH366 (Table 2). Therefore the unknown
extragenic growth-compensatory mutation(s) in this mutant
directly affects resistance levels to these two antibiotics. Because
we have not sequenced the complete genomes for any of these
mutants we cannot rule out the possibility that additional
compensatory mutations might have been selected. Collectively,
these observations demonstrate that growth compensation in the
FusA class mutants is strongly associated with second-site
mutations in fusA.
Analysis of a menadione-auxotrophic FusA SCV mutant
We previously identified an unusual FusA-SCV mutant
(AH334) that carried a mutation in fusA but also displayed
menadione-auxotrophy [18]. Sequence analysis of AH334 (CGS
and local sequencing) showed that in addition to a mutation in fusA
this mutant also carried a TGA nonsense mutation in menE, thus
providing a plausible explanation for the menadione-auxotrophy
(Table 3). Growth-compensated mutants were selected from
AH334 as described above for the other FusA-SCV mutants.
The genomes of our WT strain AH001 (NCTC 8325-4), the
menadione-auxotrophic FusA-SCV mutant (AH334), and one of 4
independently selected growth-compensated mutants (AH513)
were each analysed by CGS. The DNA sequence showed that
the growth-compensated mutant AH513 had acquired a mutation
(CRT substitution) 60 nucleotides upstream of the start codon of
menE (Table 3). By comparison with other S. aureus sequences we
drew the tentative conclusion that this mutation altered the 235
region of the menE promoter. If this conclusion were correct it
would suggest the possibility that an up-regulation of the mutant
menE gene may suppress the defect in menadione biosynthesis and
thus improve growth rate. Sequencing of the menE region of the 3
additional growth compensated mutants revealed that one of these
(AH515) had acquired the same mutation at 260 (Table 3). No
additional mutations in the menE region were identified in the
other two mutants. As with the growth compensated FusA SCV
mutants discussed above, the growth compensatory mutations
once again altered FA and KAN MICS. All 4 growth-
compensatory mutants of parent strain AH334 demonstrated
reduced MICs to both of these drugs (Table 3).
Analysis of growth-compensated FusE L6 mutants
In the FusE L6 group we predicted that mutations in rplF cause
the slow growth phenotype. These strains are phenotypically stable
and faster-growing mutants did not arise at a frequency high
enough to be consistently isolated by spreading,10
8 cfu on LA-
plates. Instead, strains AH379, AH380 and AH377 were passaged
twice in LB overnight to enrich for rare faster-growing mutants of
each strain (Table 4). The strains used in this selection had
putative knockout-mutations in rplF in the form of a stop codon
(AH379), a 21 nt frameshift (AH380) and a +1 nt frameshift
Table 2. Growth compensated mutants of FusA SCVs.
Stock SCV mutation
Compensating
mutation MIC (mg/ml)
fusA (EF-G) fusA (EF-G) KAN FA N
a
AH001 WT WT 2 0.064
AH347 Arg659Ser 48 12
AH517 Arg659Ser Gly653Ala 12 4 2
AH518 Arg659Ser Val86Ile 12 8
AH519 Arg659Ser Val86Leu 12 16
AH520 Arg659Ser Pro635ProPro 12 4
AH521 Arg659Ser Ala478Val 32 16
AH523 Arg659Ser Gly653Cys 6 3
AH350 Arg659Cys 12 12
AH524 Arg659Cys Val86Leu 8 8 2
AH525 Arg659Cys Val86Ile 8 4 3
AH527 Arg659Cys Ala217Thr 32 6
AH530 Arg659Cys Ala376Val 12 16
AH531 Arg659Cys Met616Ile 12 4
AH364 Asp434Asn 24 256
AH532 Asp434Asn Val86Ile 12 256 2
AH534 Asp434Asn Ala376Val 12 256
AH535 Asp434Asn Ala655Val 6 8
AH366 Pro114His 12 6
AH536 Pro114His Gly653Val 6 0.25 2
AH537 Reversion WT 2 0.094
AH538 Pro114His Val86Ile 8 2 2
AH539 Pro114His Ser416Tyr 12 24
AH540 Pro114His Extragenic
b 24 8
AH541 Pro114His Ile408Thr 16 16
AH542 Pro114His Gly653Ala 4 1.5
AH544 Pro114His Gly653Cys 4 0.75
aN, the number of independent isolates with the same genotype and
phenotype.
bNo compensatory mutation was identified within fusA.
doi:10.1371/journal.pone.0028366.t002
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independent selections (Table 4), these interruptions in rplF had
been reversed by nt substitutions in the stop codon (AH379-
derived mutants), downstream +1 nt frameshifts (AH380-derived
mutants) and overlapping or downstream 21 nt frameshifts
(AH377-derived mutants). In two of the AH377-derived mutants
(AH588 and AH589) the acquisition of the 21 frameshift
mutation was associated with the simultaneous acquisition of
additional base substitution mutations in an AT-rich sequence
nearby in rplF (Table 4). Interestingly, all of the selected FusE L6
growth-compensated mutants appear to be full phenotypic
revertants with respect to both colony size and FA and KAN
MICs (Table 4). We have not sequenced the genomes of these
mutants and thus cannot formally rule out the possibility that they
carry additional mutations associated either with the SCV or with
the selection for growth compensation. However, the full
phenotypic compensation noted above supports the hypothesis
that the rplF mutations alone can explain the phenotypes of slow
growth and increased FA and KAN MICs in the FusE L6 group.
Analysis of growth-compensated FusE L6-Hem and
L6-Men mutants
28 independent growth-compensated mutants were selected
from 6 mutant strains (AH339, AH384, AH386, AH362, AH351
and AH390) belonging to the FusE L6-Hem and FusE L6-Men
groups (Table 5). In all cases, the original rplF mutation of the
respective parental strain was still present in the compensated
strains (Table 5). In 3 growth-compensated mutants the original
hem or men mutation had reverted to the WT sequence (AH559,
hemB R WT; AH483 and AH488, menB R WT) (Table 5). In 4
growth-compensated mutants a second mutation had occurred in
menB: in strains AH484, AH485, and AH486, by replacement of a
nonsense codon with a sense codon; and in AH492, by the
acquisition of a second-site amino acid substitution (Table 5). One
of the growth-compensated mutants selected from AH351 (gerC3)
had acquired a single nt substitution in the predicted promoter
region upstream of the operon containing gerC (Table 5). This
suggests the possibility that an up-regulation of the expression of
the whole operon (which includes the genes gerC1, ubiE and gerC3)
can compensate for the reduced activity of the enzyme-component
encoded by the mutant gerC3. In many growth-compensated
mutants intragenic mutations were not identified by sequencing a
set of genes believed to be involved in hemin or menadione
biosynthesis (Table S1) suggesting that in some cases compensa-
tory mutations can arise in other genes.
Table 3. Growth compensated mutants of a FusA
menadione-auxotrophic SCV.
Strain SCV mutations
Compensating
mutation MIC (mg/ml)
fusA menE menE KAN FA
AH001
a WT WT 2 0.064
AH334
a Thr436Ile Trp67Stop 128 48
AH513
a Thr436Ile Trp67Stop CT (260) 16-34 12-16
AH514 Thr436Ile Trp67Stop none found. 16-34 12-16
AH515 Thr436Ile Trp67Stop CT (260) 16-34 12-16
AH516 Thr436Ile Trp67Stop none found 16-34 12-16
aAH001 (8325-4), AH334, and AH513 were also analysed by CGS.
doi:10.1371/journal.pone.0028366.t003
Table 4. Selection of growth-compensated mutants from FusE L6 SCVs.
Mutations in rplF (ribosomal protein L6)
Strain SCV mutation Compensating mutation MIC (mg/mL) N
a
KAN FA
AH001 (WT) 20 . 0 6 4
AH379 Gln140Stop (CAARTAA) 8 6
AH592 replaced TAARGAA (Glu) 2 0.064 2
AH593 replaced TAARTTA (Leu) 3 0.047 2
AH594 replaced TAARAAA (Lys) 3 0.064
AH595 replaced TAARTAT (Tyr) 3 0.064 3
AH380 21 T nt 158 8 6
AH597 21 T nt 158 +T nt 170 3 0.064 2
AH598 21 T nt 158 +C nt 173 3 0.047
AH600 21 T nt 158 +T nt 176 2 0.032
AH377 +A nt 23, KKIIDRKKNYstop 8 2
AH588
b +An t2 3 2Gn t1 8RNKIFD 3 0.064
AH589
b WT 2An t2 3RKKIFD 3 0.064
AH590
b +An t2 3 2Gn t1 8RKKIID WT 2 0.032 2
aN, the number of independent isolates with the same genotype and phenotype.
bSequence complexity of AH377 derivatives.
WT: AAG-AAA-ATT-ATT-GAC (KKIID).
AH377: AAG-AAA-AAT-TAT-TGA (KKNYstop).
AH588: AAT-AAA-ATT-TTT-GAC (NKIFD).
AH589: AAG-AAA-ATT-TTT-GAC (KKIFD), and Glu114Leu (GAARTTA).
AG590: AAA-AAA-ATT-ATT-GAC (KKIID).
doi:10.1371/journal.pone.0028366.t004
Genetic Complexity of FusR SCVs
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e28366Influence of hemin or menadione addition on KAN MIC
The data show that the KAN MIC’s of growth-compensated
FusE SCV’s are almost always intermediate between the high
MIC values of the parental SCV strain and the low, fully
susceptible, MIC value of the wild-type (Table 5). The reduced
susceptibility of hemin and menadione auxotrophic SCVs to
aminoglycoside antibiotics like KAN is thought to be associated
with defects in the proton motive force which is required for
aminoglycoside uptake [1]. We chose a representative set of the
FusE SCV mutants with identified mutations in hemB, hemH, menA,
menB and gerC (Table 5) asked whether their KAN susceptibility or
growth rates could be complemented by the addition of hemin or
menadione to the growth medium. In each case we compared the
original SCV mutant with an isogenic growth-compensated
mutant (Figure 1). The addition of hemin, but not menadione,
caused a large reduction in the KAN MIC of the hemin
auxotrophic SCVs (AH339 and AH384) whereas is had no
significant effect on the MICs of isogenic growth-compensated
Table 5. Selection of growth-compensated mutants from FusE Hemin and Menadione-auxotrophic SCVs.
Identified mutations
Mutations in men or hem genes MIC (mg/ml)
Strain rplF (L6)
a Original Intragenic KAN FA
AH001 (WT)
b 2 0.064
AH339 21F S
c nt 144 hemB Gly87Asp 256 8
AH559 21 FS nt 144 replaced hemB WT 12 4
AH384 21F Sn t2 2 1 hemH Gly209Asp 128 12
AH497
b 21F Sn t2 2 1 hemH Gly209Asp NMI
d 64 8
AH498 21F Sn t2 2 1 hemH Gly209Asp NMI 64 12
AH499 21F Sn t2 2 1 hemH Gly209Asp NMI 48 12
AH501 21F Sn t2 2 1 hemH Gly209Asp NMI 48 8
AH502 21F Sn t2 2 1 hemH Gly209Asp NMI 64 8
AH503 21F Sn t2 2 1 hemH Gly209Asp NMI 48 6
AH510 21F Sn t2 2 1 hemH Gly209Asp NMI 96 6
AH386 21F Sn t9 0 menB Gln204stop 256 12
AH482 21F Sn t9 0 menB Gln204stop NMI 48 12
AH483 21 FS nt 90 replaced menB WT 16 3
AH484 21 FS nt 90 replaced menB 204Ser 24 8
AH485 21 FS nt 90 replaced menB 204Lys 16 6
AH486 21 FS nt 90 replaced menB 204Lys 12 6
AH487 21F Sn t9 0 menB Gln204stop NMI 24 8
AH488 21 FS nt 90 replaced menB WT 24 8
AH362 TAA stop nt 282 menA Asp81Tyr 256 16
AH479 TAA stop nt 282 menA Asp81Tyr NMI 256 16
AH481 TAA stop nt 282 menA Asp81Tyr NMI 192 4
AH351 24 FS nts 45–48 gerC3 21 FS nt 919 128 12
AH472 24 FS nts 45–48 gerC3 21 FS nt 919 NMI 24 8
AH473 24 FS nts 45–48 gerC3 21 FS nt 919 NMI 32 8
AH474 24 FS nts 45–48 gerC3 21 FS nt 919 NMI 32 6
AH475 24 FS nts 45–48 gerC3 21 FS nt 919 NMI 64 12
AH476 24 FS nts 45–48 gerC3 21 FS nt 919 NMI 16 6
AH477 24 FS nts 45–48 gerC3 21 FS nt 919 NMI 16 16
AH478 24 FS nts 45–48 gerC3 21 FS nt 919 gerC TRGa t259 48 16
AH390 +1F Sn t8 4 menB Arg53Cys 256 12
AH489 +1F Sn t8 4 menB Arg53Cys NMI 32 6
AH490 +1F Sn t8 4 menB Arg53Cys NMI 48 6
AH491 +1F Sn t8 4 menB Arg53Cys NMI 64 16
AH492 +1F Sn t8 4 menB Arg53Cys menB Val128Ile 24 6
aNote that the rplF mutations were published previously [18].
bAH001 (W.T., 8325-4) and AH497 were also analysed by CGS.
cFS, frameshift mutation.
dNMI. no mutation identified.
doi:10.1371/journal.pone.0028366.t005
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hemB and hemH mutant strains was also increased by the addition
of hemin to the growth medium, to the same rate as that associated
with the selected growth-compensatory mutations in AH559 and
AH497 (Figure 1B). The addition of menadione did not alter the
growth rate of these strains. The addition of menadione, but not
hemin, caused a large reduction in the KAN MIC of the menB
auxotroph AH386 (and AH390, not shown in Figure 1) but did not
alter the MIC of AH362 (menA) or AH351 (gerC). We note that the
KAN MIC associated with the menA mutation in AH362 was also
not reduced in the isogenic growth-compensated mutant AH479.
The addition of menadione, but not hemin, increased the growth
rates of each of the menadione-auxotrophic strains to a similar rate
as that achieved by the growth-compensatory mutations
(Figure 1B). We note here that the degree of growth compensation,
whether by compensatory mutations affecting hem or men
biosynthesis genes, or by chemical complementation of auxotro-
phy through the addition of hemin or menadione to the growth
medium, is in all cases incomplete (Figure 1B). This suggests that
in these strains the rplF mutations inactivating ribosomal protein
L6 are alone sufficient to cause a severe growth defect. This is in
agreement with published data [18] showing that the SCV strains
carrying only a mutation in rplF (such as AH357, analysed by
CGS, Table 1) can have growth rates less than half that of the
wild-type strain. Chemical complementation experiments were
also made with FusA and FusE L6 mutants but in those strains the
addition of hemin or menadione caused no change in MIC KAN.
Two-step genetic reversion of an SCV phenotype
DNA sequence analysis (CGS and local sequencing) supports
the hypothesis that the slow growth phenotype of the FusE L6-
Hem and FusE L6-Men SCV mutants can be explained by the
mutations identified in rplF and hem/men genes (Table 5). If this
hypothesis were correct it would predict that it should be possible
to select a WT phenotype from such an SCV in two steps, by
reverting first one mutation, then the second. To test this we
selected growth-compensatory mutations from AH386 (Table 1).
AH386 is extremely slow growing menadione-auxotrophic SCV
(generation time 180 min in LB medium) and carries mutations in
rplF and menB. In the first-step selection for a faster-growing
mutant we isolated AH483. In AH483 the menB sequence has
reverted to the WT sequence (Gln204) and this was associated
Figure 1. The affect of the addition of hemin or menadione to the growth medium (Mueller-Hinton Broth or agar) on MIC KAN (part
A) and growth rate (part B) for isogenic strain pairs (SCVs and growth-compensated mutants). AH001 is the wild-type strain. Results
shown are the median value of six to ten independent measurements for MIC measured by Etest, and the mean of two independent measurements
of growth rate measured in a Bioscreen C machine.
doi:10.1371/journal.pone.0028366.g001
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cycled in five independent liquid overnight cultures for two days,
and two of these cultures were taken over by faster-growing cells
that were isolated as the independent mutants AH562 and AH563
that were subsequently characterized (Table 6). In AH562 the rplF
frameshift had reverted to the WT sequence (+A), while in AH563
a +G insertion in the same position had reverted the original
frameshift and replaced it with a silent mutation. Both strains
displayed colony sizes and MIC’s for FA and KAN that were
indistinguishable from the WT strain S. aureus 8325-4 (Figure 2).
The ability to revert the SCV phenotype in two steps supports the
hypothesis that the SCV phenotype in AH386 can be explained by
the two mutations identified in rplF and menB, although in the
absence of further experiments we cannot conclusively rule out the
possibility that additional mutations might also be involved.
Discussion
The FusE class of SCV’s have reduced susceptibility to FA and
aminoglycosides and carry putative knockout-mutations (frame-
shifts, nonsense codons, or mutated start codons) in rplF, the gene
coding for ribosomal protein L6. We showed previously that FusE
mutants comprised at least two distinct phenotypic groups, being
auxotrophic for either hemin, or menadione [18]. In addition,
different FusE mutants displayed large variations in growth rate as
well as in phenotypic stability. This suggested that at least some
FusE mutants must carry additional mutations to explain the
diversity in phenotypes. Here we have shown that FusE mutants
fall into three distinct genetic and phenotypic classes: the FusE L6
class (rplF single mutants, slow growing), the FusE L6-Hem class
(rplF and hem-gene double mutants, very slow growing) and the
FusE-Men class (rplF and men-gene double mutants, extremely slow
growing). CGS, localized manual sequencing, and genetic
reversion studies all support the conclusion that many of the FusE
SCV’s are double mutants. FusA-SCV mutants in contrast
typically carry only single mutations in fusA, but one unusual
variant was identified that carried an additional mutation in the
menadione biosynthesis pathway.
Because we have performed CGS on only a very limited
number of strains, we cannot rule out the possibility that
additional unidentified mutations may be present in some of our
strains and contribute to their phenotypes.
In order to link the identified mutations in FusE and FusA-SCV
strains to the phenotypes of the respective groups we selected
growth-compensated mutants that were subjected to genetic
analysis. For each of the different FusE classes we found that
reversion or intragenic mutation led to the predicted improvement
in growth. In one FusE mutant we made a two-step selection and
identified reversion of a single primary mutation at each step
(Table 6). The FusE mutants identified as double mutants (Table 1)
were selected using the aminoglycoside kanamycin. It seems
unlikely that the double mutations pre-existed in the overnight
cultures, especially at frequencies similar to the fusA and rplF single
mutants. More likely is that they are derived from mutants with
single (rplF or hem/men) mutations and that secondary mutations
arising under selection improved resistance or survival in the
presence of kanamycin. Although we identified second-site
mutations and reversions in hem and men genes when selecting
for growth compensation of SCVs, these were not always found.
This suggests that there are additional ways in which the SCV
phenotype can be ameliorated (some of these are under
investigation). We note that the level of resistance to KAN
measured in the FusE SCVs (Table 5) appears to be partly
associated with the respiratory defects caused by mutations in hem
or men genes, and partly by the mutation in ribosomal protein rplF.
Thus, the addition of hemin or menadione to the growth medium
reduces the KAN MIC of these double mutants to a level similar to
that associated with the rplF mutation alone (Figure 1 and Table 4).
These data show that even in the controlled laboratory
environment, a simple selection for resistance to one antibiotic
frequently result in the selection of different mutant variants, some
of which have complex mutant phenotypes and genotypes. Thus,
aminoglycosides selected different phenotypic variants of S. aureus
including those that were SCVs and were resistant to both
aminoglycosides and to the unrelated antibiotic fusidic acid.
Among these mutants, FusE class isolates carried mutations in one
or two of 6 different genes (rplF, hemB, hemH, menA, menB, genC).
Many of these resistant isolates had very slow growth rates in rich
medium and under selection for faster growth the typically evolved
by acquiring additional mutations. This mode of compensatory
Figure 2. Illustration of a FusE L6-Men SCV derived from S.
aureus 8325-4, and how it was evolved back to normal growth
by selecting for faster-growing mutants in two steps (clock-
wise). A. S. aureus AH001 (WT), normal growth; B. AH386, FusE L6-Men
SCV (rplF, menB); C. AH483 (rplF, menB WT); D. AH562 normal growth
(rplF WT, menB WT).
doi:10.1371/journal.pone.0028366.g002
Table 6. Selection of growth-compensated mutants from an
SCV in two steps.
SCV mutations MIC (mg/ml)
Strain rplF menB KAN FA
AH001 WT WT 2 0.064
AH386 2A nt 90 Gln204UAG (Stop) 256 12
AH483 2A nt 90 Stop204Gln (WT) 16 3
AH562 +A nt 90 Lys (AAA=WT) WT 2 0.064
AH563 +G nt 90 Lys (AAG) WT 2 0.064
doi:10.1371/journal.pone.0028366.t006
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these isolates. While many of the SCV mutants initially selected for
resistance may be removed by natural selection for growth rate,
many of those that survive can be expected to undergo further
evolution, with the accumulation of additional mutations, some
associated with selection for resistance and other associated with
selection for restoration of growth or survival fitness.
Materials and Methods
Strains and growth conditions
FusA SCV and FusE SCV mutants were selected from the drug-
susceptible laboratory wild-type (WT) strain S. aureus 8325-4
(AH001), as previously described [18]. Bacterial cultures were
grown in Luria broth (LB), or on solid Luria agar plates (LA) unless
otherwise stated. Liquid cultures were incubated overnight (18 h)
at 37uC with shaking at 200 rpm. Bacterial strain stocks were
stored frozen in LB + DMSO (7%) at 280uC. Maximum
exponential growth rates were measured in a Bioscreen C (OY
Growth Systems, Finland) and are based on 6–8 independent
measurements for each strain and condition.
Selection of fast-growing compensated mutants or
revertants from SCVs
Independent SCV colonies from various strains were suspended
in 0.9% NaCl, diluted, plated on LA and visually inspected for
faster-growing colonies following overnight growth (37uC). Colo-
nies were then picked, restreaked, and stocked. DNA sequencing
was used to determine if these faster-growing mutants had
acquired intragenic compensatory mutations or reversions in any
of the mutations associated with the SCV phenotype of the strain.
MIC assays
The minimal inhibitory concentration was measured using Etest
strips (BioMe ´rieux) in accordance with the manufacturers’
recommendations. Initially, a single colony was dissolved in 1 ml
0.9% NaCl to a density of 0.5 McFarland units, and a cotton swab
was used to spread the bacterial suspension over the surface of a
Mueller-Hinton plate (Difco Becton Dickinson, MD, USA). After
the application of the Etest strip, plates were incubated at 37uC for
18–24 h until growth of the bacterial lawn was evident.
PCR and DNA sequencing
Template DNA was prepared by initially dissolving a bacterial
colony in 100 ml ddH2O and placing this cell suspension in a
microfuge tube. Next,,100 ml of 0.25 mm acid washed glass
beads (Sigma-Aldrich AB, Stockholm, Sweden, cat no. G1277)
was added to the cell suspensions which were then vortexed
violently for 10 sec to disrupt the cell walls. Primers for amplifying
and sequencing S. aureus genes were designed based on the publicly
available genome sequences. The standard PCR sequence for our
gene amplifications began with a denaturation step of 5 min at
95uC, followed by 30 cycles of 15 sec at 95uC, 15 sec at 45uC and
1 min/kb 72uC. The last elongation step was prolonged to 5 min.
Sequencing reactions were carried out at Macrogen Inc. (Seoul,
Korea) and sequences were then analyzed using Vector NTI
10.3.0 (Invitrogen, Carlsbad, CA) and BioEdit (http://www.mbio.
ncsu.edu/BioEdit/bioedit.html), a freely available sequence align-
ment editor. Twelve different genes associated with hemin
biosynthesis, including their predicted promoter regions, were
sequenced in all hemin-auxotrophic SCV strains (Table S1). Nine
different genes associated with menadione biosynthesis, including
their predicted promoter regions, were sequenced in all menadi-
one-auxotrophic SCV strains (Table S1).
Comparative genome sequencing
CGS services provided by Roche NimbleGen Inc. (Madison,
WI, USA) were utilized for whole genome mutation mapping
comparing parent strain AH001 (NCTC 8325-4) with fusidic acid-
resistant SCV NCTC 8325-4 mutants. A S. aureus NCTC 8325
genome (Genbank accession: CP000253.1) tiling array was used to
hybridize test and reference genomic DNA, and single nucleotide
polymorphisms in each strain were identified based on previously
defined criteria [24]. The number of SNP’s called by CGS was up
to 30 per genome sequence. Each of these putative mutations was
subjected to manual re-sequencing of the relevant genes and the
great majority (with the exception of those named in this paper)
were eliminated as false positives. The SNP’s called by CGS
included all of those expected to be present in each genome on the
basis of prior manual sequencing, with the exception of one
frameshift mutation in rplF (AH358) which was not called but was
confirmed by manual re-sequencing.
Supporting Information
Table S1 The following genes including predicted promoter
regions (given here with locus tags and product names from the
NCTC 8325 genome, GenBank accession number CP000253.1,
available at http://www.ncbi.nlm.nih.gov/), were sequenced in all
menadione-auxotrophic or hemin-auxotrophic SCV strains. If
gene names were not annotated in NCTC 8325 then the names
were taken from a closely related S. aureus genome, usually S. aureus
COL (GenBank: CP000046.1, available at http://www.ncbi.nlm.
nih.gov/).
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